MDS
Showing NaN - NaN of 10
Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)
Not yet recruiting
- Acute Myeloid Leukemia
- +6 more
-
Boston, Massachusetts
- +1 more
Mar 31, 2023
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (Orca-T,
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Orca-T
- Standard-of-Care
-
Duarte, California
- +13 more
Jan 25, 2023
Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts Trial in Worldwide (rigosertib, Any approved or
Terminated
- Myelodysplastic Syndrome
- +3 more
- rigosertib
- +2 more
-
La Jolla, California
- +157 more
Sep 22, 2022
Hematologic Malignancy, AML, ALL Trial in Australia, United States (Tagraxofusp, Fludarabine, Cytarabine)
Not yet recruiting
- Hematologic Malignancy
- +10 more
- Tagraxofusp
- +8 more
-
Los Angeles, California
- +28 more
Jul 26, 2022
MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)
Terminated
- MDS
- Myelodysplastic Syndromes
- APR-548 + Azacitidine
-
Tampa, Florida
- +3 more
Jul 20, 2022
GVHD, AML, ALL Trial in Boston (FLUDARABINE, CYCLOPHOSPHAMIDE, TBI)
Recruiting
- GVHD
- +15 more
- FLUDARABINE
- +6 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 30, 2021
Myelodysplastic Syndrome, MDS Trial in Canada, United States (ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727
Completed
- Myelodysplastic Syndrome
- MDS
- ASTX727 Dose Escalation
- +2 more
-
Phoenix, Arizona
- +16 more
Dec 1, 2020
MDS, MDS, RAEB Trial in Worldwide (ON 01910.Na)
Completed
- Myelodysplastic Syndromes
- +3 more
- ON 01910.Na
-
Scottsdale, Arizona
- +86 more
Jun 29, 2020
AML, CML, MDS Trial in Boston, New York, San Antonio (STA-9090 (ganetespib))
Completed
- AML
- +3 more
- STA-9090 (ganetespib)
-
Boston, Massachusetts
- +2 more
Sep 17, 2014